Compare BBAR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBAR | PTGX |
|---|---|---|
| Founded | 1886 | 2006 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 9.3B |
| IPO Year | 1997 | 2016 |
| Metric | BBAR | PTGX |
|---|---|---|
| Price | $12.41 | $139.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $25.00 | ★ $174.69 |
| AVG Volume (30 Days) | 472.4K | ★ 535.2K |
| Earning Date | 08-27-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | N/A | N/A |
| Revenue This Year | $55.59 | $1,078.44 |
| Revenue Next Year | $18.23 | N/A |
| P/E Ratio | ★ $26.78 | $60.03 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $62.24 |
| 52 Week High | $22.47 | $160.81 |
| Indicator | BBAR | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 28.19 | 44.31 |
| Support Level | $12.62 | $132.37 |
| Resistance Level | $17.05 | $142.20 |
| Average True Range (ATR) | 0.46 | 4.59 |
| MACD | -0.10 | -0.44 |
| Stochastic Oscillator | 8.94 | 39.61 |
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.